The estimated Net Worth of Julius Knowles is at least $41.5 Milion dollars as of 3 January 2022. Julius Knowles owns over 47,651 units of Keros Therapeutics stock worth over $12,741,803 and over the last 5 years Julius sold KROS stock worth over $28,760,607.
Julius has made over 18 trades of the Keros Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Julius sold 47,651 units of KROS stock worth $2,756,134 on 3 January 2022.
The largest trade Julius's ever made was selling 95,302 units of Keros Therapeutics stock on 27 September 2021 worth over $3,923,583. On average, Julius trades about 24,913 units every 27 days since 2020. As of 3 January 2022 Julius still owns at least 232,727 units of Keros Therapeutics stock.
You can see the complete history of Julius Knowles stock trades at the bottom of the page.
Julius's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Over the last 5 years, insiders at Keros Therapeutics have traded over $50,765,607 worth of Keros Therapeutics stock and bought 2,504,088 units worth $46,191,339 . The most active insiders traders include Ran Nussbaum, Carl L Gordon a Tomer Kariv. On average, Keros Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $3,312,649. The most recent stock trade was executed by Carl L Gordon on 13 August 2024, trading 250,000 units of KROS stock currently worth $11,002,500.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics executives and other stock owners filed with the SEC include: